CheckMate-9DX: Phase 3, Randomized, Double-Blind Study of Adjuvant Nivolumab vs Placebo for Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence after Curative Resection or Ablation
SIR ePoster library. Jimenez Exposito M. 03/23/19; 261245; 526
Maria Jesus Jimenez Exposito
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Discussion Forum (0)
Rate & Comment (0)
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}